US 12,318,432 B2
BCG and IL-15 based molecules
Bai Liu, Culver City, CA (US); Peter Rhode, Culver City, CA (US); Wenxin Xu, Culver City, CA (US); and Hing C. Wong, Culver City, CA (US)
Assigned to Altor Bioscience, LLC, Culver City, CA (US)
Filed by Altor Bioscience, LLC, Culver City, CA (US)
Filed on Jun. 7, 2024, as Appl. No. 18/737,465.
Application 18/737,465 is a division of application No. 18/639,659, filed on Apr. 18, 2024.
Application 18/639,659 is a division of application No. 18/394,409, filed on Dec. 22, 2023, granted, now 12,097,244.
Application 18/063,871 is a division of application No. 17/825,959, filed on May 26, 2022, granted, now 11,679,144, issued on Jun. 20, 2023.
Application 15/921,512 is a division of application No. 14/755,989, filed on Jun. 30, 2015, granted, now 9,925,247, issued on Mar. 27, 2018.
Application 18/394,409 is a continuation of application No. 18/063,871, filed on Dec. 9, 2022, granted, now 11,890,323, issued on Feb. 6, 2024.
Application 17/825,959 is a continuation of application No. 16/925,138, filed on Jul. 9, 2020, granted, now 11,471,511, issued on Oct. 18, 2022.
Application 16/925,138 is a continuation of application No. 16/444,807, filed on Jun. 18, 2019, granted, now 11,173,191, issued on Nov. 16, 2021.
Application 16/444,807 is a continuation of application No. 15/921,512, filed on Mar. 14, 2018, granted, now 10,537,615, issued on Jan. 21, 2020.
Claims priority of provisional application 62/018,899, filed on Jun. 30, 2014.
Prior Publication US 2024/0307495 A1, Sep. 19, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/74 (2015.01); A61K 38/17 (2006.01); A61K 38/20 (2006.01); A61K 39/395 (2006.01); A61K 47/64 (2017.01); A61P 35/00 (2006.01); A61K 39/04 (2006.01); C07K 14/35 (2006.01); C07K 14/54 (2006.01); C07K 14/715 (2006.01); C07K 16/28 (2006.01)
CPC A61K 38/2086 (2013.01) [A61K 38/1793 (2013.01); A61K 39/39558 (2013.01); A61K 47/6425 (2017.08); A61P 35/00 (2018.01); A61K 39/04 (2013.01); C07K 14/35 (2013.01); C07K 14/5443 (2013.01); C07K 14/7155 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/2887 (2013.01); C07K 16/2896 (2013.01); C07K 2317/732 (2013.01); C07K 2319/30 (2013.01); C07K 2319/32 (2013.01)] 3 Claims
OG exemplary drawing
 
1. A kit for use in treating a neoplasia in a human subject, the kit comprising:
a first vial consisting essentially of 50 mg of Bacille Calmette-Guerin (BCG) formulated for administration to the subject;
a second vial consisting essentially of 400 μg of an IL-15N72D: IL-15RαSu/Fc complex (ALT-803) formulated for administration to the subject, wherein said ALT-803 comprises a dimeric IL-15RαSu/Fc and two IL-15N72D molecules; and
instructions for said use thereof.